There are currently 212 clinical trials in Springfield, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Southern Illinois University School of Medicine, Memorial Medical Center, Springfield Clinic and Central Illinois Hematology Oncology Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: SIU Simmons Cancer Institute, Springfield, Illinois
Conditions: Multiple Myeloma
Register for Updates
Collection of Samples USOPTIVAL Study
NCT04792684
Recruiting
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
Gender:
All
Ages:
Between 45 years and 84 years
Trial Updated:
01/26/2023
Locations: Springfield Clinic, Springfield, Illinois
Conditions: Colorectal Cancer (CRC), Advanced Adenomas (AA)
Register for Updates
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Southern Illinois University School of Medicine, Springfield, Illinois +2 locations
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
NCT04873232
Recruiting
To evaluate the durability of efficacy and long-term safety of intramuscular (IM) administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Foot & Ankle Center of Illinois, Springfield, Illinois
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
NCT04962139
Recruiting
The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by the blinded independent evaluator.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
07/15/2022
Locations: Oneness Investigational Site, Springfield, Illinois
Conditions: Chronic Diabetic Foot Ulcers
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Southern Illinois University School of Medicine, Springfield, Illinois
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
NCT04753385
Recruiting
The objective of this study is to collect both active and passive data using a wearable, multi-sensor device (Verily Study Watch) and phone application (Mood App) which aims to capture mental health status, in subjects participating in the RECOVER clinical trial (A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: Southern Illinois University School of Medicine, Springfield, Illinois
Conditions: Treatment Resistant Depression
Register for Updates
NOVOCART®3D for Treatment of Articular Cartilage of the Knee
NCT01957722
Recruiting
This study is to compare NOVOCART 3D relative to Microfracture for the treatment of knee cartilage defects. Efficacy will be evaluated by both pain and function. Safety will also be evaluated.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/01/2022
Locations: Siu School of Medicine, Springfield, Illinois
Conditions: Articular Cartilage of the Femoral Condyle Between 2-6cm2
Register for Updates